OptimizeRx (OPRX) grants 34,517 restricted stock units to director

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

KLEMA CATHY reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director Cathy Klema reported an equity grant of 34,517 restricted stock units (RSUs) tied to the company’s common stock. The RSUs were awarded on June 9, 2026 at no cash purchase price and represent a contingent right to receive shares.

The RSUs will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders. Following this grant, Klema’s direct holdings reported in the filing total 56,137 shares of common stock. The transaction is characterized as a grant or award rather than an open-market buy or sell.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KLEMA CATHY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,517	$0.00	--

Holdings After Transaction: Common Stock — 56,137 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 34,517 units Transaction price: $0.00 per unit Holdings after grant: 56,137 shares +2 more

5 metrics

RSUs granted 34,517 units Restricted stock units granted on June 9, 2026

Transaction price $0.00 per unit Grant/award acquisition, not open-market purchase

Holdings after grant 56,137 shares Total OptimizeRx common shares directly held after transaction

Vesting trigger Earlier of 1 year or next meeting Vests on first anniversary of grant or next annual meeting of shareholders

Grant date June 9, 2026 Date restricted stock unit grant was awarded

Key Terms

restricted stock units, contingent right, annual meeting of shareholders, grant, award, or other acquisition

4 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"representing a contingent right to receive shares of OptimizeRx common stock"

annual meeting of shareholders financial

"the date of the Company's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 01:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KLEMA CATHY

(Last)

(First)

(Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM

MASSACHUSETTS

02459

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/09/2026		A		34,517⁽¹⁾	A	$0	56,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person fi ling this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the benefi cialowner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be fi led by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did OptimizeRx (OPRX) director Cathy Klema report?

OptimizeRx director Cathy Klema reported receiving 34,517 restricted stock units linked to common stock. These RSUs are a grant recorded at no cash purchase price and increase her reported direct holdings to 56,137 shares following the transaction.

Is Cathy Klema’s OptimizeRx (OPRX) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant, not an open-market purchase. It records an award of 34,517 restricted stock units representing a contingent right to receive OptimizeRx common shares, with no cash price per unit listed in the transaction details.

When do Cathy Klema’s 34,517 OptimizeRx (OPRX) RSUs vest?

The 34,517 restricted stock units will vest in full on the earlier of two dates: the first anniversary of the June 9, 2026 grant date or the date of OptimizeRx’s next annual meeting of shareholders, according to the footnote description.

How many OptimizeRx (OPRX) shares does Cathy Klema hold after this Form 4 grant?

After the reported grant, the Form 4 lists Cathy Klema as directly holding 56,137 shares of OptimizeRx common stock. This figure reflects her position following the award of 34,517 restricted stock units disclosed in the transaction.

What does the zero transaction price on Cathy Klema’s OptimizeRx (OPRX) Form 4 mean?

A transaction price of zero indicates the award was not an open-market purchase. Instead, the 34,517 units are a grant of restricted stock units, representing a contingent right to receive shares under the terms described in the Form 4 footnote.